Your browser is no longer supported. Please, upgrade your browser.
Settings
BPTH Bio-Path Holdings, Inc. daily Stock Chart
BPTH [NASD]
Bio-Path Holdings, Inc.
Index- P/E- EPS (ttm)-14.52 Insider Own5.62% Shs Outstand2.52M Perf Week16.76%
Market Cap47.93M Forward P/E- EPS next Y- Insider Trans-31.27% Shs Float2.37M Perf Month-11.53%
Income-8.60M PEG- EPS next Q- Inst Own28.50% Short Float25.36% Perf Quarter654.76%
Sales- P/S- EPS this Y10.10% Inst Trans- Short Ratio0.14 Perf Half Y70.37%
Book/sh1.79 P/B10.63 EPS next Y- ROA-178.60% Target Price15.00 Perf Year-42.71%
Cash/sh0.40 P/C47.93 EPS next 5Y- ROE-225.60% 52W Range1.61 - 73.52 Perf YTD443.43%
Dividend- P/FCF- EPS past 5Y-9.50% ROI- 52W High-74.13% Beta3.50
Dividend %- Quick Ratio1.70 Sales past 5Y- Gross Margin- 52W Low1081.37% ATR3.08
Employees9 Current Ratio1.70 Sales Q/Q- Oper. Margin- RSI (14)53.45 Volatility14.50% 11.73%
OptionableNo Debt/Eq0.00 EPS Q/Q29.50% Profit Margin- Rel Volume0.08 Prev Close20.22
ShortableYes LT Debt/Eq0.00 EarningsMar 20 BMO Payout- Avg Volume4.15M Price19.02
Recom- SMA201.41% SMA5030.44% SMA20025.07% Volume350,689 Change-5.93%
Nov-13-17Reiterated H.C. Wainwright Buy $4.50 → $1.50
Aug-10-16Reiterated Maxim Group Buy $5 → $2
Apr-18-16Initiated Rodman & Renshaw Buy $5
Jun-02-14Resumed Maxim Group Buy $5
May-09-14Initiated Maxim Group Buy $5
Apr-15-19 04:33PM  How This Highly Rated Biotech Stock Added To Its Meteoric Run Investor's Business Daily +32.52%
01:01PM  Bio-Path Holdings News: Why BPTH Stock Is Skyrocketing Today InvestorPlace
10:46AM  Bio-Path's stock rockets after withdrawal of stock offering MarketWatch
Apr-03-19 08:00AM  Bio-Path Holdings Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2019 GlobeNewswire
Mar-21-19 06:13AM  Should You Buy Bio-Path Stock After 5-Fold Gain? 3 Pros, 3 Cons InvestorPlace -14.05%
Mar-20-19 09:15AM  Bio-Path Holdings Reports Full Year 2018 Financial Results GlobeNewswire -14.68%
06:30AM  Bio-Path Holdings, Inc. to Host Earnings Call ACCESSWIRE
Mar-15-19 04:01PM  Bio-Path Holdings to Announce Fourth Quarter and Full Year 2018 Financial Results on March 20, 2019 GlobeNewswire +7.03%
Mar-14-19 03:10PM  Bio-Path Holdings, Inc. Announces Closing of $18.5 Million Registered Direct Offering of Common Stock Business Wire -11.53%
Mar-12-19 09:15AM  Bio-Path Holdings, Inc. Announces $18.5 Million Registered Direct Offering of Common Stock GlobeNewswire +8.29%
Mar-08-19 01:25PM  The Secret To Trading Stocks Like Bio-Path That Helped Me Quit My Desk Job And Make Thousands Benzinga -45.96%
07:30AM  The Device Market That Drove One Company From $2.50 to $65 Has a New Entrant ACCESSWIRE
Mar-07-19 11:55AM  Traders Mystified by 3000% Surge in Shares of Cancer-Drug Maker Bloomberg +223.29%
10:35AM  UPDATE: Bio-Path stock gains another 130% on Thursday MarketWatch
Mar-06-19 02:35PM  Bio-Path Holdings Updates Clinical Trial Data and it Sounds Promising ACCESSWIRE +160.46%
01:27PM  Bio-Path Holdings News: Why BPTH Stock Is Skyrocketing Today InvestorPlace
10:00AM  Under the Radar Cannabis Stock-THC Therapeutics, Inc. ACCESSWIRE
08:00AM  Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia GlobeNewswire
Mar-04-19 06:10AM  Is Bio-Path Holdings, Inc.s (NASDAQ:BPTH) CEO Pay Justified? Simply Wall St. -28.76%
Feb-28-19 08:00AM  Bio-Path Holdings to Present Data at the 2019 AACR Annual Meeting GlobeNewswire +28.71%
Jan-24-19 04:30PM  Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) ACCESSWIRE
Jan-23-19 04:01PM  Bio-Path Holdings, Inc. Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market GlobeNewswire +10.50%
Jan-18-19 12:31PM  Bio-Path Holdings, Inc. Announces $1.7 Million Registered Direct Offering Priced At-the-Market GlobeNewswire -30.56%
08:00AM  Bio-Path Holdings Announces 1-for-20 Reverse Stock Split GlobeNewswire
Jan-17-19 04:07PM  Bio-Path Holdings, Inc. Announces Closing of Public Offering of Common Stock GlobeNewswire
Jan-16-19 08:24AM  The Daily Biotech Pulse: Revance Common Stock Offering, Adcom Catalyst For Amgen Benzinga
Jan-14-19 10:23PM  Bio-Path Holdings, Inc. Announces Pricing of Public Offering of Common Stock GlobeNewswire -12.96%
04:01PM  Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire
Dec-27-18 08:49AM  Bio-Path Holdings Provides Clinical Update and 2019 Business Outlook GlobeNewswire
Dec-26-18 09:47AM  Could Bio-Path Holdings, Inc.s (NASDAQ:BPTH) Investor Composition Influence The Stock Price? Simply Wall St. -24.73%
Dec-03-18 07:22AM  Bio-Path Holdings Presents Interim Data from Phase 2 Study Evaluating Prexigebersen as a Treatment for Acute Myeloid Leukemia at the 60th Annual American Society of Hematology Annual Meeting GlobeNewswire -22.11%
Nov-25-18 09:41AM  The Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings Benzinga
Nov-15-18 07:20AM  Bio-Path: 3Q Earnings Snapshot Associated Press
07:00AM  Bio-Path Holdings Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-08-18 04:01PM  Bio-Path Holdings to Announce Third Quarter 2018 Financial Results on November 15, 2018 GlobeNewswire
Nov-01-18 09:05AM  Bio-Path Holdings to Present Clinical Data at the 60th Annual American Society of Hematology Annual Meeting GlobeNewswire +7.47%
Oct-09-18 01:11PM  What does Bio-Path Holdings Incs (NASDAQ:BPTH) Balance Sheet Tell Us About Its Future? Simply Wall St.
Sep-25-18 04:01PM  Bio-Path Holdings, Inc. Announces Closing of $1.5 Million Registered Direct Offering GlobeNewswire
Sep-21-18 06:30AM  Bio-Path Holdings, Inc. Announces $1.5 Million Registered Direct Offering GlobeNewswire -36.46%
Aug-29-18 08:00AM  Bio-Path Holdings to Present at the H.C. Wainwright 20th Annual Global Investment Conference GlobeNewswire -6.00%
Aug-27-18 07:30AM  Bio-Path Holdings Announces First Patient Dosed in Expansion of Phase 2 Trial of Prexigebersen in Acute Myeloid Leukemia GlobeNewswire
Aug-16-18 10:26AM  Bio-Path Holdings Appoints Dr. Jason B. Fleming to Scientific Advisory Board GlobeNewswire -5.33%
Aug-15-18 07:05AM  Bio-Path: 2Q Earnings Snapshot Associated Press +6.38%
07:00AM  Bio-Path Holdings Reports Second Quarter 2018 Financial Results GlobeNewswire
06:30AM  Bio-Path Holdings, Inc. to Host Earnings Call ACCESSWIRE
Aug-08-18 09:15AM  Bio-Path Holdings to Announce Second Quarter 2018 Financial Results on August 15, 2018 GlobeNewswire +5.82%
Jun-26-18 08:00AM  Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) ACCESSWIRE
May-16-18 08:11AM  With A -19.42% Earnings Drop, Is Bio-Path Holdings Incs (NASDAQ:BPTH) A Concern? Simply Wall St.
07:08AM  Bio-Path: 1Q Earnings Snapshot Associated Press
07:00AM  Bio-Path Holdings Reports First Quarter 2018 Financial Results GlobeNewswire
May-10-18 08:00AM  Bio-Path Holdings Appoints Dr. Anas Younes to Scientific Advisory Board GlobeNewswire
May-09-18 08:00AM  Bio-Path Holdings to Announce First Quarter 2018 Financial Results on May 16, 2018 GlobeNewswire
Apr-18-18 04:01PM  Pre-Clinical Data Demonstrating Promising Potential of Prexigebersen as Treatment for Solid Tumors in Gynecologic Malignancies Presented at American Association for Cancer Research Annual Meeting GlobeNewswire
Apr-09-18 07:20AM  Wired News EMA Completed Validation of MAA for Aradigms Linhaliq in Non-Cystic Fibrosis Bronchiectasis ACCESSWIRE -5.21%
Apr-04-18 11:15AM  Bio-Path Leukemia Combo Study Shows Positive Early Data Zacks -9.50%
Apr-03-18 12:03PM  Bio-Path: Why the Biotech Penny Stock Is Skyrocketing Today InvestorPlace +24.86%
08:35AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:30AM  Bio-Path Holdings Reports Full Year 2017 Financial Results GlobeNewswire
07:15AM  Bio-Path Holdings Announces Interim Data from Phase 2 Clinical Trial of Prexigebersen in Combination with Low Dose Cytarabine (LDAC) for the Treatment of Acute Myeloid Leukemia (AML) GlobeNewswire
06:30AM  Bio-Path Holdings, Inc. to Host Earnings Call ACCESSWIRE
Mar-29-18 08:00AM  Bio-Path Holdings Announces Publication in The Lancet Haematology GlobeNewswire
Mar-27-18 04:15PM  Bio-Path Holdings to Announce Fourth Quarter and Full Year 2017 Financial Results on April 3, 2018 GlobeNewswire
Mar-15-18 07:00AM  Bio-Path Holdings to Present Data at the 2018 AACR Annual Meeting GlobeNewswire +7.02%
Mar-06-18 07:00AM  Bio-Path Holdings to Present at the 30th Annual ROTH Conference GlobeNewswire
Feb-09-18 07:00AM  Bio-Path Holdings Announces 1-for-10 Reverse Stock Split GlobeNewswire
Feb-05-18 04:01PM  Bio-Path Holdings to Present at the BIO CEO & Investor Conference GlobeNewswire
08:00AM  Bio-Path Holdings Appoints Paul Aubert to its Board of Directors GlobeNewswire
Dec-29-17 04:01PM  Bio-Path Holdings Provides Clinical Update and 2018 Business Outlook GlobeNewswire
Dec-15-17 04:30PM  Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) ACCESSWIRE
Nov-13-17 07:20AM  Corporate News Blog - Valeant Pharma Completes Sale of its Obagi Medical Products Business ACCESSWIRE -5.16%
Nov-10-17 06:25AM  Bio-Path Holdings Inc (BPTH): How Does It Impact Your Portfolio? Simply Wall St.
Nov-09-17 05:11PM  Bio-Path reports 3Q loss Associated Press
04:01PM  Bio-Path Holdings Reports Third Quarter 2017 Financial Results GlobeNewswire
Nov-06-17 08:00AM  Bio-Path Holdings Highlights Advancements in Preclinical Discovery Efforts GlobeNewswire
Nov-03-17 09:20AM  Bio-Path Holdings, Inc. Announces $4 Million Registered Direct Offering GlobeNewswire -17.82%
08:00AM  Bio-Path Holdings to Announce Third Quarter 2017 Financial Results on November 10, 2017 GlobeNewswire
Oct-23-17 04:30PM  Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) ACCESSWIRE -5.13%
Oct-11-17 03:14PM  Is It Time To Buy Bio-Path Holdings Inc (BPTH)? Simply Wall St. -12.58%
Sep-05-17 08:00AM  Bio-Path Holdings to Present at the Rodman & Renshaw Annual Healthcare Conference GlobeNewswire
Aug-10-17 11:54PM  Bio-Path reports 2Q loss Associated Press -13.04%
07:00AM  Bio-Path Holdings Reports Second Quarter 2017 Financial Results GlobeNewswire
Aug-03-17 08:30AM  Bio-Path Holdings to Announce Second Quarter 2017 Financial Results on August 10, 2017 GlobeNewswire
Jul-19-17 08:00AM  Bio-Path Holdings Receives Notice of Allowance for Key U.S. Composition of Matter Patent GlobeNewswire
Jul-17-17 08:00AM  Bio-Path Holdings Appoints Mark Colonnese to its Board of Directors GlobeNewswire
Jun-29-17 04:30PM  Stonegate Capital Partners Initiates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) Accesswire
May-11-17 09:01AM  Bio-Path reports 1Q loss Associated Press -8.49%
07:00AM  Bio-Path Holdings Reports First Quarter 2017 Financial Results GlobeNewswire
May-04-17 08:00AM  Bio-Path Holdings to Announce First Quarter 2017 Financial Results on May 11, 2017 GlobeNewswire
Apr-17-17 08:45AM  Bio-Path Holdings (BPTH) Looks Good: Stock Moves 13% Higher Zacks +13.80%
08:00AM  Bio-Path Holdings Announces Appointment of Dr. William Hahne as Vice President of Clinical Development GlobeNewswire
Apr-05-17 08:01AM  Bio-Path Holdings Presents Results Showing Potential of BP1002 as Treatment for Aggressive Non-Hodgkins Lymphoma GlobeNewswire
08:01AM  Bio-Path Holdings Presents Results Showing Potential of BP1002 as Treatment for Aggressive Non-Hodgkins Lymphoma
Mar-21-17 01:04PM  BIO-PATH HOLDINGS INC Financials
Mar-15-17 08:30AM  Bio Path Holdings Inc Earnings Call scheduled for 8:30 am ET today
07:36AM  Bio-Path reports 4Q loss Associated Press
07:36AM  Bio-Path reports 4Q loss
07:11AM  BIO-PATH HOLDINGS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Fi
07:04AM  BIO-PATH HOLDINGS INC Files SEC form 10-K, Annual Report
07:00AM  Bio-Path Holdings Reports Full Year 2016 Financial Results GlobeNewswire
Mar-14-17 08:00AM  Bio-Path Holdings to Present at the Oppenheimer 27th Annual Healthcare Conference GlobeNewswire
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and chronic myelogenous leukemia; and in preclinical studies for solid tumors, including breast cancer and ovarian cancer. The company is also developing Liposomal Bcl2 for the treatment of lymphoma; and Liposomal Stat3 that is in preclinical stage for the treatment of pancreatic cancer. It has license agreement with The University of Texas relating to the delivery technology platform for antisense nucleic acids, including two single nucleic acid drug products. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ARMISTICE CAPITAL, LLC10% OwnerJan 18Sale2.6664,457171,643129,298Jan 23 06:15 PM